It is a known fact that your race has a profound effect on your health status. Confirming that study is a research held at University of Massachusetts and Pennsylvania which shows that race/ethnicity is a predictor of plasma lipids in patients with HIV-1 on HAART (highly active antiretroviral therapy).
The study was conducted on 626 patients participating in several ongoing AIDS Clinical Trial Group studies. The main thrust was to look at the way that race/ethnicity, genetic variants of lipoproteins apoC-III/apoA-I, and protease inhibitors (a class of drugs used against HIV) affected plasma lipids.
Overall, Black patients on HAART had a lipid profile more likely to be less prone to atheroma than White and Hispanic patients.
HIV-1 infection has become a chronic, manageable condition for patients who have long-term access to highly active antiretroviral therapy. Some protease inhibitors have been associated with elevated levels of cholesterol, triglyceride, and low high-density lipoprotein cholesterol.
These findings are believed to be the first evidence for race/ethnicity-specific differences in both the occurrence of dyslipidemia on antiretroviral therapy (ART) and the influence of genetic factors on the occurrence of protease inhibitor-related lipid abnormalities.